64
Participants
Start Date
January 9, 2017
Primary Completion Date
August 8, 2022
Study Completion Date
August 8, 2022
LN-145
A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration.
LN-145-S1
A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with autologous TIL (LN-145-S1) followed by IL-2 administration.
UPMC Hillman Cancer Center, Pittsburgh
Christiana Care Health System, Newark
University of Maryland, Baltimore
University of North Carolina, Chapel Hill
Moffitt Cancer Center, Tampa
University of Alabama, Birmingham
University of Louisville, Louisville
Indiana University, Indianapolis
Barbara Ann Karmanos Cancer Institute, Detroit
Medical College of Wisconsin, Milwaukee
Avera Cancer Institute, Sioux Falls
Northwestern University, Chicago
University of Chicago, Chicago
University of Kansas, Westwood
Louisiana State University - Health Sciences Center, New Orleans
University of Colorado, Aurora
University of California, Los Angeles, Los Angeles
University of Southern California, Los Angeles
University of California San Diego, La Jolla
Providence Cancer Center Oncology and Hematology Care Clinic, Portland
University of Washington, Seattle
Morristown Medical Center, Morristown
Lead Sponsor
Iovance Biotherapeutics, Inc.
INDUSTRY